The role of relative lymphocyte count as a new biomarker for the effect of catumaxomab on overall survival in patients with malignant ascites: Follow-up results from a phase ll/lll study

Category Primary study
JournalJournal of Clinical Oncology
Year 2011
This article has no abstract
Epistemonikos ID: f131445a5e841eb494c1a2a077b1f36bc05bf3f1
First added on: Feb 04, 2025